Trametinib for pancreatic cancer – pro
Trametinib, an oral mitogen/extracellular signal-related kinase (MEK)1/2 inhibitor, holds promise for malignancies with rat sarcoma (RAS) mutations, like pancreas cancer. However, the only phase II trial (Infatne et al) did not show effectiveness. The addition of trametinib to gemcitabine did not improve OS, PFS, ORR or DOR in patients with previously untreated metastatic pancreas cancer.
NCCN, Pancratic Cancer 2019
Trametinib, Prescribing INformation 2018
Infante JRA et al, Randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.Eur J Cancer. 2014 Aug;50(12):2072-81.